Genmab A/S (NASDAQ:GMAB) Receives “Buy” Rating from HC Wainwright

Genmab A/S (NASDAQ:GMAB)‘s stock had its “buy” rating reissued by HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They presently have a $50.00 price target on the stock. HC Wainwright’s target price indicates a potential upside of 125.43% from the company’s current price.

GMAB has been the topic of several other research reports. Morgan Stanley reaffirmed an “equal weight” rating and issued a $31.00 price objective on shares of Genmab A/S in a research report on Wednesday, September 11th. Sanford C. Bernstein upgraded Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. BMO Capital Markets reissued an “outperform” rating and set a $48.00 price objective (up from $46.00) on shares of Genmab A/S in a report on Friday, November 8th. Finally, Redburn Atlantic began coverage on Genmab A/S in a research note on Tuesday, October 8th. They issued a “buy” rating on the stock. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Genmab A/S has an average rating of “Moderate Buy” and a consensus price target of $45.20.

Genmab A/S Trading Up 1.5 %

Shares of GMAB opened at $22.18 on Wednesday. The stock has a 50 day moving average of $21.33 and a 200 day moving average of $24.28. Genmab A/S has a 12 month low of $19.85 and a 12 month high of $32.88. The company has a market capitalization of $14.68 billion, a price-to-earnings ratio of 21.53, a PEG ratio of 0.63 and a beta of 0.97.

Genmab A/S (NASDAQ:GMAB) last announced its earnings results on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). The business had revenue of $816.10 million for the quarter, compared to analysts’ expectations of $838.20 million. Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. During the same period in the prior year, the business earned $0.47 earnings per share. As a group, equities research analysts predict that Genmab A/S will post 1.28 earnings per share for the current year.

Hedge Funds Weigh In On Genmab A/S

Large investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp lifted its holdings in Genmab A/S by 4.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 70,171 shares of the company’s stock worth $1,763,000 after purchasing an additional 3,283 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of Genmab A/S by 7.1% in the second quarter. Rhumbline Advisers now owns 18,694 shares of the company’s stock worth $470,000 after buying an additional 1,236 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Genmab A/S by 360.8% in the second quarter. Acadian Asset Management LLC now owns 38,010 shares of the company’s stock valued at $954,000 after acquiring an additional 29,762 shares during the period. Choreo LLC purchased a new position in Genmab A/S during the second quarter valued at approximately $776,000. Finally, Headlands Technologies LLC increased its holdings in Genmab A/S by 1,702.8% during the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock worth $129,000 after acquiring an additional 4,853 shares during the period. 7.07% of the stock is owned by institutional investors.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.